Certolizumab Pegol: Clinical Trials

132 trials of Certolizumab Pegol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

92 completed, 14 unknown, 10 terminated, 9 recruiting. 60 Phase 3, 22 Phase 4, 17 Phase 2, 8 Phase 1, 6 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 360Completed 49, Withdrawn 4, Terminated 3, Recruiting 2, Unknown 2
Phase 422Completed 10, Unknown 7, Terminated 4, Not yet recruiting 1
Phase 217Completed 13, Recruiting 3, Terminated 1
Phase 18Completed 8
Not applicable6Unknown 3, Recruiting 2, Completed 1

Follow Certolizumab Pegol: new trials by email Literature Review of Certolizumab Pegol trials Research Report on Certolizumab Pegol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis
Phase 4Not yet recruitingUniversity of California, San Francisco102026-08-012026-06-03
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease
Phase 2RecruitingNYU Langone Health802025-12-122026-07-09
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Tociliuzumab, Infliximab, Adalimumab - Takayasu Arteritis
Not applicableRecruitingMarmara University402025-06-152026-03-25
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease
This is an observational study with no intervention. Patients will receive anti- TNF therapy as part of their standard care - IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
RecruitingShmuel Kivity, MD402025-01-042026-06-12
Certolizumab in Recurrent Implantation Failure (RIF)
Certolizumab (CIMZIA® ; TNF-α antagonist), Placebo (NaCl 0.9 % solution) - Recurrent Unexplained Implantation Failure
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris1612023-11-302023-12-11
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Ozanimod, TNF Inhibitor, Steroids - Ulcerative Colitis
UnknownInsel Gruppe AG, University Hospital Bern2402023-09-062023-12-06
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
Placebo, Nipocalimab, Certolizumab - Arthritis, Rheumatoid
Phase 2CompletedJanssen Research & Development, LLC1032023-08-152025-10-16
The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients
Anti-TNF, JAK inhibitor - Rheumatoid Arthritis
Phase 3WithdrawnAbu Dhabi Stem Cells Center2023-03-012025-10-06
Stand UP to Rheumatoid Arthritis (SUPRA)
TNFi, Anti-IL6, JAKi - Rheumatoid Arthritis
Not applicableRecruitingMarie Hudson, MD752023-02-012026-02-03
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Cisplatin, Pemetrexed, Gemcitabine - Lung Cancer, Lung Cancer Stage II
Phase 2RecruitingMemorial Sloan Kettering Cancer Center602022-10-192026-10-02
Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis
Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) - Rheumatoid Arthritis
Not applicableUnknownMedical University of Vienna852022-03-012021-11-15
Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis
Tapered doses of TNFi, Standard dose of TNFi - Axial Spondyloarthritis
Phase 4UnknownUniversity Health Network, Toronto152021-12-012024-01-17
COVID-19 VaccinE Response in Rheumatology Patients
Upadacitinib, Abatacept, Secukinumab - Rheumatoid Arthritis, Psoriatic Arthritis
Phase 4CompletedJeffrey Curtis8412021-11-152025-05-02
The Clinical Features and Pregnancy Outcomes of RA Patients
Prednisone, Hydroxychloroquine, CertolizumabPegol injection - Rheumatoid Arthritis, Pregnancy Related
UnknownQilu Hospital of Shandong University1002021-07-302022-12-15
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
Certolizumab pegol, Adalimumab, Placebo - Crohn's Disease
Phase 3WithdrawnUCB Biopharma SRL2021-06-012021-06-23
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints
Tofacitinib, TNF Inhibitor - Rheumatoid Arthritis
CompletedBrigham and Women's Hospital1057112021-03-102022-06-22
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints
Tofacitinib, TNF Inhibitor - Rheumatoid Arthritis
CompletedBrigham and Women's Hospital1057112021-02-222022-03-02
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
Certolizumab pegol - Rheumatoid Arthritis
Phase 1CompletedUCB Biopharma SRL332021-02-112024-02-12
Treatment of Pregnancy RA
Certolizumab Pegol 200 MG/ML [Cimzia], Hydroxychloroquine, Prednisone - Rheumatoid Arthritis, Pregnancy Related
Not applicableUnknownRenJi Hospital1002020-12-012020-10-01
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
Prednisolone, Sulfasalazine, Leflunomide - Psoriatic Arthritis, Withdrawal
Phase 3UnknownUniversity of Erlangen-Nürnberg Medical School2702020-10-192022-11-14

Showing 20 of 132. Sign in to see all of them.

Conditions studied

Arthritis, Rheumatoid (68)  ·  Crohn Disease (33)  ·  Arthritis, Psoriatic (9)  ·  Psoriasis (7)  ·  Spondylitis, Ankylosing (7)  ·  Axial Spondyloarthritis (6)  ·  Inflammatory Bowel Diseases (6)  ·  Arthritis (5)  ·  Colitis, Ulcerative (4)  ·  Spondylarthritis (4)  ·  Joint Diseases (3)  ·  Spondylarthropathies (3)  ·  Anemia, Dyserythropoietic, Congenital (2)  ·  Arthritis, Juvenile (2)  ·  Autoimmune Diseases (2)

Sponsors

UCB Pharma (36)  ·  UCB Biopharma SRL (8)  ·  UCB BIOSCIENCES GmbH (6)  ·  UCB Pharma SA (6)  ·  UCB Biopharma S.P.R.L. (5)  ·  Astellas Pharma Inc (4)  ·  Brigham and Women's Hospital (3)  ·  UCB BIOSCIENCES, Inc. (3)  ·  University of Erlangen-Nürnberg Medical School (3)  ·  Karolinska Institutet (2)  ·  Korea Otsuka Pharmaceutical Co., Ltd. (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Otsuka Pharmaceutical Co., Ltd. (2)  ·  Shafran Gastroenterology Center (2)  ·  UCB Celltech (2)

Countries

United States (67)  ·  Canada (30)  ·  Germany (30)  ·  Czechia (23)  ·  France (23)  ·  Poland (23)  ·  Belgium (17)  ·  Italy (17)  ·  Hungary (16)  ·  United Kingdom (16)  ·  Netherlands (15)  ·  Austria (14)  ·  Spain (13)  ·  Australia (12)  ·  Russia (12)

Top investigators

Ira Shafran, M.D. (2)  ·  Katsuhisa Saito (2)  ·  Ronald van Vollenhoven, MD, Prof. (2)  ·  Ayal Hirsch, MD (1)  ·  Benjamin Misselwitz, Prof. (1)  ·  Bincy P. Abraham, MD, MS (1)  ·  Bogdan Batko, MD, PhD (1)  ·  Carlo M Taboada, MD (1)  ·  Charles W Randall, MD (1)  ·  Christian Dejaco, MD, PhD (1)  ·  Christopher Ritchlin, MD / MPH (1)  ·  Costantino Pitzalis, MD PhD FRCP (1)

Results publications

PMID 29246162, PMID 32100960, PMID 32531798, PMID 17634466, PMID 19015207, PMID 19877104, PMID 20547658, PMID 21484766, PMID 22413944, PMID 22589265, PMID 26238672, PMID 26353833, PMID 27165179, PMID 27696727, PMID 28376912, PMID 28666080, PMID 29030361, PMID 29660421, PMID 32652544, PMID 36509889, PMID 40256636, PMID 42263998, PMID 17634458, PMID 17634459, PMID 18071721, PMID 18343277, PMID 18975346, PMID 19015206, PMID 19222413, PMID 19471252, PMID 19909548, PMID 20117244, PMID 20298497, PMID 20363366, PMID 20451663, PMID 20491747, PMID 20799264, PMID 21083671, PMID 21223344, PMID 21362764, PMID 21415050, PMID 21443536, PMID 21485024, PMID 21642014, PMID 21884592, PMID 22231904, PMID 22344576, PMID 22525883, PMID 22596211, PMID 22923753

NIH funding

2014 (9), 2005 (7), 2009 (4), 2015 (2), 2004 (1), 2008 (1), 2016 (1), 2017 (1), 2023 (1), R01HL127118 (1)